Related StoriesMD Anderson study reveals why chemotherapy medicines not effective for many pancreatic cancer patientsFDA grants accelerated acceptance for Tagrisso to take care of individuals with advanced NSCLCCrucial change in single DNA base predisposes children to intense form of cancerCTCA at Midwestern individuals are evaluated using state-of-the-art diagnostic equipment to identify the tumor and stage of the disease. ‘Our patient-centered style of care ensures sufferers and their own families are engaged, key and informed decision makers from day one.Â.. CTCA at Midwestern named Certified Quality Breasts Center of Excellence Cancer CENTERS of America at Midwestern Regional INFIRMARY has been recognized by the National Quality Steps for Breast Centers Plan to be among the top centers in the united states for providing quality breasts cancer treatment.Alnylam reported today that it provides formed a new contract with a pharmaceutical partner to judge Alnylam's Biotherapeutics technology, which aims to make use of RNAi systems to boost the manufacturing processes for biologics. Regulus Formed Strategic Alliances and Completed Preliminary Public Offering . Regulus and AstraZeneca entered into a strategic alliance targeted at advancing microRNA therapeutics for three microRNA targets centered on cardiovascular and metabolic diseases and oncology, all of which are in pre-clinical development. AstraZeneca produced a payment of $28 million, which includes an equity expenditure and an upfront payment to Regulus.